Solesence, Inc.
- SLSN · Nasdaq
- Perfumes, Cosmetics & Other Toilet Preparations
- Romeoville, IL
- 115 employees
- CIK 0000883107
Updated from SEC filings through
Top things to know
Executives
- Jess Jankowski President and Chief Executive Officer 10-K, 2026-03-31
- Kevin Cureton President and Chief Executive Officer 10-K, 2026-03-31
- Laura Riffner Chief Financial Officer 10-K, 2026-03-31
- Laura C. Riffner Chief Financial Officer 3, 2025-10-06
What leadership is saying
“In the second quarter, our business focused on operational execution and financial discipline as we continue implementing our Transform and Transcend strategy”
Earnings press release (8-K Ex. 99.1), filed August 20, 2026
Solesence, Inc. is a U.S. public company in perfumes, cosmetics & other toilet preparations (SIC 2844), headquartered in Romeoville, IL. It trades as SLSN on Nasdaq. Revenue was $62.1M in the fiscal year ending December 31, 2025, +18.6% from the year before. It reported about 115 employees. Jess Jankowski is President and Chief Executive Officer.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $62.1M 10-K, 2026-03-31 | $52.3M 10-K, 2026-03-31 | $37.3M 10-K, 2025-03-31 | $37.3M 10-K, 2024-03-28 | $29.5M 10-K, 2023-03-29 |
| Operating income | $1.6M 10-K, 2026-03-31 | $5.1M 10-K, 2026-03-31 | -$3.5M 10-K, 2025-03-31 | -$2.3M 10-K, 2024-03-28 | $2.6M 10-K, 2023-03-29 |
| SG&A | $10.4M 10-K, 2026-03-31 | $7.2M 10-K, 2026-03-31 | $7.5M 10-K, 2025-03-31 | $7.6M 10-K, 2024-03-28 | $3.9M 10-K, 2023-03-29 |
| Net income | $1.8M 10-K, 2026-03-31 | $4.2M 10-K, 2026-03-31 | -$4.4M 10-K, 2025-03-31 | -$2.6M 10-K, 2024-03-28 | $2.3M 10-K, 2023-03-29 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Jess Jankowski | President and Chief Executive Officer | 10-K, 2026-03-31 |
| Kevin Cureton | President and Chief Executive Officer | 10-K, 2026-03-31 |
| Laura Riffner Chief Financial Officer | Catalyst for Strategic Business Transformation and Operational Excellence | Chief Financial Officer | 10-K, 2026-03-31 |
| Laura C. Riffner | Chief Financial Officer | 3, 2025-10-06 |
What Solesence, Inc. does
Solésence, along with its wholly owned subsidiary, Solésence, LLC (our “Solésence consumer products subsidiary”), is a leading innovator in scientifically driven health care solutions across beauty, health and wellness categories, protecting skin from environmental aggressors and enhancing the aesthetic appeal of health-enhancing products.
Item 1. Business, 10-K for the year ending December 31, 2025
Shares and governance
| Shares outstanding | 70.6 million (as of August 19, 2026) | 10-Q, August 19, 2026 |
|---|---|---|
| Public float | $27.3M (as of June 30, 2025) | 10-K, March 31, 2026 |
| Latest proxy statement | Meeting August 28, 2025 (filed July 30, 2025) | DEF 14A, July 30, 2025 |
| Auditor | Rsm Us LLP (Milwaukee, Wisconsin) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| December 24, 2025 | R. Janet Whitmore Director | Buy | 2,500 | $5K | Form 4, December 30, 2025 |
| November 19, 2025 | R. Janet Whitmore Director | Buy | 35,056 | $63K | Form 4, December 11, 2025 |
Recent 8-K events
- 8-K filed 2026-10-05
- Item 1.01 Entry into a material definitive agreement
- 8-K filed 2026-10-02
- Item 3.01 Notice of delisting or failure to meet listing standards
- 8-K filed 2026-08-21
- Item 4.02 Non-reliance on previously issued financial statements
- 8-K filed 2026-08-20
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-07-10
- Item 1.01 Entry into a material definitive agreement
- 8-K filed 2026-05-12
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-04-29
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2026-03-31
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2025-12-03
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2025-12-01
- Item 1.01 Entry into a material definitive agreement
- Item 5.02 Departure or appointment of directors or officers; compensation
Frequently asked questions about Solesence, Inc.
- What does Solesence, Inc. do?
- In its own words, from Item 1 of its 10-K: "Solésence, along with its wholly owned subsidiary, Solésence, LLC (our “Solésence consumer products subsidiary”), is a leading innovator in scientifically driven health care solutions across beauty, health and wellness categories, protecting skin from environmental aggressors and enhancing the aesthetic appeal of health-enhancing products."
- What is Solesence, Inc.'s revenue?
- $62.1M for the fiscal year ending December 31, 2025, from its 10-K filed March 31, 2026.
- Is Solesence, Inc. profitable?
- Solesence, Inc. reported net income of $1.8M for the fiscal year ending December 31, 2025.
- How many employees does Solesence, Inc. have?
- About 115 as of December 31, 2025, as stated in its annual report.
- Who is the CEO of Solesence, Inc.?
- Jess Jankowski, President and Chief Executive Officer, as named in a 10-K filed March 31, 2026.
- Who is the CFO of Solesence, Inc.?
- Laura Riffner, Chief Financial Officer, as named in a 10-K filed March 31, 2026.
- Where is Solesence, Inc. headquartered?
- Romeoville, IL.
- What is Solesence, Inc.'s stock ticker?
- SLSN on Nasdaq.
- What industry is Solesence, Inc. in?
- Perfumes, Cosmetics & Other Toilet Preparations, SIC code 2844.
- What is Solesence, Inc.'s website?
- solesence.com.
- When does Solesence, Inc. report earnings next?
- November 10, 2026. Source: pg_future_events.
- Is Solesence, Inc. a public company?
- Yes. Solesence, Inc. files with the SEC under CIK 0000883107 and trades as SLSN.
- Who audits Solesence, Inc.?
- Rsm Us LLP, Milwaukee, Wisconsin, as named in its latest annual report (10-K).
- How many shares of Solesence, Inc. are outstanding?
- 70.6 million shares as of August 19, 2026, from its 10-Q filed August 19, 2026.
- What is Solesence, Inc.'s public float?
- $27.3M as of June 30, 2025, as reported on the cover of its 10-K filed March 31, 2026.
- When is Solesence, Inc.'s annual shareholder meeting?
- August 28, 2025, per its proxy statement (DEF 14A) filed July 30, 2025.
- Have Solesence, Inc. insiders traded stock recently?
- Since November 19, 2025, officers and directors reported 0 open-market sales and 2 purchases worth about $68K on Forms 4 and 5. The most recent: R. Janet Whitmore (Director) bought 2,500 shares on December 24, 2025.